🏢 公司NewsroomTVTXCodex · 实盘不做把握 2/10
北京时间·🕒 发布 00:30:00·⟳ 抓取 04:35:40回填·⚡ 决策 07-29 04:41:37 +4h11m·90.7 天前
Travere Therapeutics宣布将披露2026年二季度财报
公司仅发布二季度财报披露时间安排，没有披露收入、利润、指引、产品销售或监管进展等新增基本面信息。
📄 原文TVTX↗ 原文
Travere Therapeutics to Report Second Quarter 2026 Financial Results
Travere Contact Us Careers Facebook Instagram LinkedIn Twitter YouTube Our Company Who We Are Leadership & Board Patien…
不做 Travere Therapeutics（TVTX.US）
仅为例行财报披露日程公告，没有业绩数据、指引变化或产品进展，无法形成同向可执行交易。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-28 · 扩散 low · price-in 风险 high ↗
关键理由
- 公司仅发布二季度财报披露时间安排，没有披露收入、利润、指引、产品销售或监管进展等新增基本面信息。
主要风险
- 后续正式财报可能带来可交易信息，但本条排期公告本身不构成交易催化。
原文全文
展开原文 · 1,068 字
Travere Therapeutics to Report Second Quarter 2026 Financial Results | Travere
Contact Us
Careers
Facebook
Instagram
LinkedIn
Twitter
YouTube
Our Company
Who We Are
Leadership & Board
Patient Advocacy
Our Culture in Action
Grant Programs
Advocacy & Charitable Grants
ISR Grants
Med Ed Grants
Company News
Our Science
Our Pipeline
Pegtibatinase
Therapeutic Areas
IgA Nephropathy (IgAN)
Focal Segmental Glomerulosclerosis (FSGS)
Classical Homocystinuria (HCU)
Cystinuria
Clinical Trials
Expanded Access
Publications
Medical Affairs
Our Therapies
Rare Life
Investors & Media
Travere Therapeutics to Report Second Quarter 2026 Financial Results
View Full Press Release
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
↑ Return to Top
Terms & Conditions
Privacy
Your Privacy Choices
© 2026 Travere Therapeutics, Inc. All rights reserved. For U.S. audiences. Total Care Hub®, Travere TotalCare®, and Filspari® are registered trademarks of Travere Therapeutics. Thiola® and Thiola EC® are registered trademarks of Mission Pharmacal Company.
Contact Us
Careers
YouTube
Our Company
Who We Are
Leadership & Board
Patient Advocacy
Our Culture in Action
Grant Programs
Advocacy & Charitable Grants
ISR Grants
Med Ed Grants
Company News
Our Science
Our Pipeline
Pegtibatinase
Therapeutic Areas
IgA Nephropathy (IgAN)
Focal Segmental Glomerulosclerosis (FSGS)
Classical Homocystinuria (HCU)
Cystinuria
Clinical Trials
Expanded Access
Publications
Medical Affairs
Our Therapies
Rare Life
Investors & Media
Travere Therapeutics to Report Second Quarter 2026 Financial Results
View Full Press Release
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
↑ Return to Top
Terms & Conditions
Privacy
Your Privacy Choices
© 2026 Travere Therapeutics, Inc. All rights reserved. For U.S. audiences. Total Care Hub®, Travere TotalCare®, and Filspari® are registered trademarks of Travere Therapeutics. Thiola® and Thiola EC® are registered trademarks of Mission Pharmacal Company.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。